# CD19 CAR-T Therapy for Patients With Newly Diagnosed High-risk Large B-cell Lymphoma

> **NCT04661020** · PHASE2 · RECRUITING · sponsor: **Zhejiang University** · enrollment: 40 (estimated)

## Conditions studied

- Large B-Cell Lymphoma (LBCL)

## Interventions

- **DRUG:** CD19 CAR-T cells

## Key facts

- **NCT ID:** NCT04661020
- **Lead sponsor:** Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-12-03
- **Primary completion:** 2026-12-20
- **Final completion:** 2026-12-20
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-04-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04661020

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04661020, "CD19 CAR-T Therapy for Patients With Newly Diagnosed High-risk Large B-cell Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04661020. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*